Albert Seymour - FIXX Old Chief Scientific Officer
| FIXXDelisted Stock | USD 1.09 0.06 5.83% |
Executive
Mr. Albert Seymour Ph.D. is the Chief Scientific Officer of the company since 2016.
| Age | 56 |
| Tenure | 9 years |
| Phone | 781 301 7277 |
| Web | https://www.homologymedicines.com |
FIXX Old Management Efficiency
The company has return on total asset (ROA) of (0.364) % which means that it has lost $0.364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9002) %, meaning that it created substantial loss on money invested by shareholders. FIXX Old's management efficiency ratios could be used to measure how well FIXX Old manages its routine affairs as well as how well it operates its assets and liabilities.FIXX Old currently holds 1.32 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. FIXX Old has a current ratio of 8.27, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about FIXX Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Huw Nash | Stoke Therapeutics | 57 | |
| Cintia PharmD | Adaptimmune Therapeutics Plc | 50 | |
| Dr JD | 4D Molecular Therapeutics | 53 | |
| An Song | 4D Molecular Therapeutics | N/A | |
| Eden Fucci | Passage Bio | N/A | |
| Gregory Fuest | Passage Bio | N/A | |
| Stuart Henderson | Passage Bio | N/A | |
| Sue Browne | Passage Bio | N/A | |
| Christopher Simms | 4D Molecular Therapeutics | 49 | |
| John Lunger | Adaptimmune Therapeutics Plc | 55 | |
| FAAAAI FAAP | 4D Molecular Therapeutics | 63 | |
| Erika Jones | Black Diamond Therapeutics | 40 | |
| MD BA | Adaptimmune Therapeutics Plc | 61 | |
| Karen Carothers | 4D Molecular Therapeutics | 73 | |
| Dana Lynch | Adaptimmune Therapeutics Plc | N/A | |
| Dennis Williams | Adaptimmune Therapeutics Plc | N/A | |
| Shamim MS | Stoke Therapeutics | 65 | |
| BA ACA | Adaptimmune Therapeutics Plc | 55 | |
| Uneek Mehra | 4D Molecular Therapeutics | 53 | |
| Kerry Sharp | Adaptimmune Therapeutics Plc | N/A | |
| Jason Hoitt | Stoke Therapeutics | 46 | |
Management Performance
| Return On Equity | -0.9 | |||
| Return On Asset | -0.36 |
FIXX Old Leadership Team
Elected by the shareholders, the FIXX Old's board of directors comprises two types of representatives: FIXX Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of FIXX. The board's role is to monitor FIXX Old's management team and ensure that shareholders' interests are well served. FIXX Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, FIXX Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael MBA, Chief Officer | ||
| Melissa Gelormini, Senior Resources | ||
| Saswati Chatterjee, CoFounder Board | ||
| CPA Michaud, Corporate Finance | ||
| Paul JD, President COO | ||
| Deborah Kinch, Chief Officer | ||
| Julie MD, Sr Operations | ||
| Theresa McNeely, Chief Advocate | ||
| Cara Mayfield, Director Communications | ||
| Albert Seymour, Chief Scientific Officer |
FIXX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is FIXX Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.9 | |||
| Return On Asset | -0.36 | |||
| Operating Margin | (78.85) % | |||
| Current Valuation | (27 M) | |||
| Shares Outstanding | 3.23 M | |||
| Shares Owned By Insiders | 9.20 % | |||
| Shares Owned By Institutions | 46.75 % | |||
| Number Of Shares Shorted | 338.72 K | |||
| Price To Earning | (10.00) X | |||
| Price To Book | 0.04 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in FIXX Stock
If you are still planning to invest in FIXX Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the FIXX Old's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |